HOUSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the 2025 ThinkEquity Conference taking place October 30 at the Mandarin Oriental in New York City. FibroBio ...

Core Viewpoint - FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, with over 275 patents issued and pending [1][3]. Company Presentation - The company will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10 at 12:00 p.m. ET and will be available for one-on-one investor meetings throughout the event [2]. Company Overview - FibroBiologics is based in Houston and is developing a pipeline of treatments targeting chronic diseases, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer [3]. - The company represents a new generation of medical advancements in cell therapy and tissue regeneration [3].

Core Insights - FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblast technology, holding over 275 patents [1][6] - The company will present its recent research on fibroblast-based technology for wound healing and psoriasis at the Advanced Wound Care Summit on July 15, 2025 [1][2] Company Overview - FibroBiologics is based in Houston and is developing a pipeline of treatments aimed at chronic diseases, including diabetic foot ulcers, multiple sclerosis, and cancer [6] - The company emphasizes a novel approach to treatment that leverages the body's natural regenerative processes rather than merely managing symptoms [2][6] Upcoming Events - The Advanced Wound Care Summit will take place from July 15 to 17, 2025, in Boston, featuring global leaders in wound care innovation and clinical research [3] - The presentation by CEO Pete O'Heeron is scheduled for July 15, 2025, at 2 p.m. ET at the Marriott Courtyard Boston Downtown [3]

Core Insights - FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblast technology [1][4] - The company will present updates on its recent milestones and research at the BIO International Convention 2025, highlighting advancements in wound healing, multiple sclerosis, and psoriasis [1][2] Company Overview - FibroBiologics holds over 275 patents issued and pending, covering various clinical pathways including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer [4] - The company aims to transform the treatment landscape for chronic diseases by addressing underlying biological dysfunction rather than merely managing symptoms [2][4] Upcoming Events - The presentation at the BIO International Convention is scheduled for June 17, 2025, at 10:45 a.m. ET, at the Boston Convention & Exhibition Center [2] - The company is set to begin a Phase 1/2 clinical trial for diabetic foot ulcers later this year, marking a significant step in its research efforts [2]

Core Insights - FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics and potential cures for chronic diseases using fibroblast cells and materials [1][3] - The company holds over 240 patents issued and pending, covering various clinical pathways including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer [3] - Hamid Khoja, Ph.D., the Chief Scientific Officer, will present at The Cell & Gene Meeting On The Mediterranean in Rome, highlighting a fibroblast cell-based therapeutic approach targeting chronic inflammation-mediated diseases [1][2] Company Overview - FibroBiologics is based in Houston and represents a new generation of medical advancements in cell therapy and tissue regeneration [3] - The company is actively engaged in the development of a pipeline of treatments aimed at chronic diseases, leveraging its extensive patent portfolio [3] Conference Details - The presentation titled "Restoring Immune system homeostasis using a fibroblast cell-based therapeutic targeting three chronic inflammation-mediated diseases" will take place on April 16, 2025, at 9:00 AM CEST [2] - The event is a significant gathering for the Advanced Therapy Medicinal Products community from Europe and beyond [1][2]

Core Insights - FibroBiologics, Inc. has opened a new laboratory facility to enhance its research capabilities for chronic disease therapeutics using fibroblast technology [1][2][3] - The new facility spans over 10,000 square feet and will support in-house GMP manufacturing for drug product candidates [2][3] - The expansion aims to accelerate innovation, increase research efficiency, and reduce reliance on external partners [3] Company Overview - FibroBiologics is a clinical-stage biotechnology company based in Houston, focusing on developing treatments and potential cures for chronic diseases through fibroblast cells and materials [6] - The company holds over 240 patents issued and pending, covering various clinical pathways including wound healing, multiple sclerosis, and cancer [6] Future Plans - The company plans to hire additional researchers to support the new laboratory and its mission to combat chronic diseases [2][3] - The expansion is expected to facilitate the exploration of a broader pipeline of therapeutic candidates and enhance collaboration among research teams [3]